Spar-Gone: Cephalon Drops Sparlon Following "Non-Approvable" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA also extends user fee date for Nuvigil to December to analyze safety data.
You may also be interested in...
Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On
Cephalon’s follow-on to the sleep disorder agent Provigil could be on the market by summer, despite “approvable” letter announced March 30.
Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On
Cephalon’s follow-on to the sleep disorder agent Provigil could be on the market by summer, despite “approvable” letter announced March 30.
FDA Warning Letter Cites Cephalon For Broadening Provigil Indications
Promotion incorrectly suggests modafinil is safe and effective for various disorders associated with fatigue and sleepiness, DDMAC says.